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Abstract
Introduction The purpose of this study is to evaluate apparent
diffusion coefficient (ADC) maps to distinguish anti-vascular
and anti-tumor effects in the course of anti-angiogenic
treatment of recurrent high-grade gliomas (rHGG) as com-
pared to standard magnetic resonance imaging (MRI).
Methods This retrospective study analyzed ADC maps
from diffusion-weighted MRI in 14 rHGG patients during
bevacizumab/irinotecan (B/I) therapy. Applying image
segmentation, volumes of contrast-enhanced lesions in T1
sequences and of hyperintense T2 lesions (hT2) were
calculated. hT2 were defined as regions of interest (ROI)
and registered to corresponding ADC maps (hT2-ADC).
Histograms were calculated from hT2-ADC ROIs. There-
after, histogram asymmetry termed “skewness” was calcu-
lated and compared to progression-free survival (PFS) as
defined by the Response Assessment Neuro-Oncology
(RANO) Working Group criteria.
Results At 8–12 weeks follow-up, seven (50%) patients
showed a partial response, three (21.4%) patients were
stable, and four (28.6%) patients progressed according to
RANO criteria. hT2-ADC histograms demonstrated statis-
tically significant changes in skewness in relation to PFS at
6 months. Patients with increasing skewness (n=11)
following B/I therapy had significantly shorter PFS than
did patients with decreasing or stable skewness values (n=
3, median percentage change in skewness 54% versus −3%,
p=0.04).
Conclusion In rHGG patients, the change in ADC histo-
gram skewness may be predictive for treatment response
early in the course of anti-angiogenic therapy and more
sensitive than treatment assessment based solely on RANO
criteria.
Keywords Recurrent high-grade glioma . Anti-angiogenic
therapy . DWI-MRI . ADC histograms . Skewness
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Introduction
Essentially all patients suffering from high-grade glioma
(HGG) develop recurrent or progressive disease following
first-line standard therapy including surgery, radiotherapy,
and concomitant/adjuvant chemotherapy [1, 2].
Bevacizumab, a humanized monoclonal antibody
binding to and inhibiting the vascular endothelial
growth factor (VEGF), has shown efficacy as a single
anti-angiogenic agent or in combination with chemo-
therapy (e.g., irinotecan) in recurrent HGG (rHGG) [3].
Although bevacizumab treatment results in high radio-
graphic response rates with rapidly decreasing contrast-
enhanced tumor parts [3], response assessment with
standard Macdonald criteria [4] has become unreliable
during anti-angiogenic therapy. The rapidly seen decrease
in contrast enhancement results in large part from
restoration of abnormally high blood–brain barrier perme-
ability, often accompanied by tumor edema reduction.
Thus, anti-angiogenic treatment makes it difficult to
distinguish between anti-vascular and true anti-tumor
effects [5].
Addressing the issue of a more precise tumor response
assessment, new standardized Response Assessment Neuro-
Oncology (RANO) Working Group criteria for HGG were
recently proposed [5]. The RANO criteria also consider
non-enhanced T2/fluid-attenuated inversion recovery
(FLAIR) sequences in addition to the Macdonald criteria.
T2/FLAIR signal abnormality, however, is a combination of
infiltrating tumor cells, edema, gliosis, and treatment-
related leukoencephalopathy [6] that is also problematic
for reliable assessment of true tumor treatment response.
Diffusion-weighted MRI (DW-MRI) is able to yield
ultrastructural information on cellular density and proper-
ties of the extracellular matrix [7] and has been linked to
lesion aggressiveness and tumor response [8]. DW-MRI
measures the effective displacement of water molecules
allowed to migrate for a given time. In a large extracellular
volume, which may be caused by fluid accumulation (e.g.,
tumor edema), the apparent diffusion coefficient (ADC) is
high. In contrast, hypercellularity (e.g., compact tumor
cells) restricts diffusion by decreasing the extracellular
volume, thus, giving low ADC values. Therefore, changes
in DW-MRI may constitute an effective, highly reproduc-
ible and early predictive biomarker for both vascular
disruptive drugs and apoptosis-inducing therapies [9–12].
Mean ADC decrease and pre-therapeutic ADC values were
reported to be predictive for anti-angiogenic therapy
response [13, 14]. Important to note is the fact that HGG
are very heterogeneous tumors with different regions of
cellularity and levels of malignant transformation within the
tumor and that the ADC represents to some degree
cellularity and/or edema in a lesion [15].
This retrospective study aimed to evaluate ADC changes
during anti-angiogenic therapy in certain HGG tumor
regions. For this reason, ADC gray scale value distribution
was analyzed and expressed in histograms. The study
hypothesis was that anti-angiogenic therapy induces alter-
ations in tissue composition reflected in characteristic
changes in histogram shape and skewness. The study also
aimed to analyze whether these ADC histogram changes
could serve as an early predictive marker for therapy
response in correlation with progression-free survival (PFS)
at 6 months.
Patients and methods
Patient population (Table 1) Retrospective data acquisition
and evaluation was approved by the local ethics committee.
From 2008 to 2010, a total of 14 patients with rHGG were
treated biweekly with bevacizumab 10 mg/kg and irinote-
can 125 or 340 mg/m2 (depending on the use of enzyme-
inducing anti-epileptic drugs) according to the protocol of
Vredenburgh et al. [3].
According to disease course, rHGG patients were
differentiated in six histologically confirmed cases of
primary glioblastoma multiforme (GBM), one gliosarcoma,
and seven secondary GBMs (of these, three progressions
were histologically confirmed and four were diagnosed
following MRI). The study cohort consisted of five female
and nine male patients. At initial diagnosis, mean age was
53 years, and Karnofsky performance status (KPS) ranged
between 60% and 100% (mean, 90%). At commencement
of anti-angiogenic treatment, KPS ranged between 50% and
100% (mean, 70%). Nine patients showed right hemispher-
ic and five patients showed left hemispheric tumor local-
izations (for further details on tumor localization, refer to
Table 1).
At initial tumor manifestation, all 14 patients underwent
surgery (five gross total and eight partial tumor resections,
one stereotactic biopsy) and radiation therapy (extended
tumor field, cumulative maximum dose of 60 Gy). In
addition, ten patients received concomitant and adjuvant
Temodal chemotherapy according to the Stupp protocol
[16], and two patients received adjuvant procarbazine,
lomustine, vincristine (PCV) chemotherapy.
During the course of disease and prior to bevacizumab/
irinotecan (B/I) therapy, our patient cohort developed
between one and five recurrences, which were treated
individually with re-challenge temozolomide, sunitinib
malate (Sutent® according to the SURGE 01-07 study
protocol), PCV chemotherapy, anthracyclines (Caelyx®),
liposomal cytosin arabinoside (Depocyt®, treatment of
meningeosis gliomatosa), and re-irradiation. Patients also
received steroids as clinically demanded. Ten patients were
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on steroids at the time of initial imaging (dose range, 4–
16 mg dexamethasone daily). Four patients took steroids
throughout the entire B/I treatment course; in six patients,
steroid administration was discontinued during anti-
angiogenic therapy. Four patients never received steroids.
Progression-free survival (PFS) was counted from the
beginning of anti-angiogenic therapy to radiologic progres-
sion seen on T1 post-contrast or T2 images (RANO
criteria). Mean PFS was 4.7 months and varied between
1.5 and 10.2 months. Three patients showed no progression
at their 6-month follow-up (PFS6), and two were
progression-free at the time of study evaluation
(18.9 months and 19.9 months, respectively). Mean overall
survival (OS), defined as from the date of initial diagnosis
to death, was 59 months and varied between 16.4 and
169.5 months. Three patients were still alive at study
evaluation (patients no. 9, 81.9 months; no. 10,
45.7 months; and no 13, 119.7 months). During B/I
treatment, clinical assessment and KPS were obtained
every 2 weeks. Standard MRI scans and diffusion-
weighted imaging were performed every 8–12 weeks. All
scans of the 14 patients were evaluable for T1 and T2
volumetry as well as for ADC map image analysis.
MR imaging MRI studies were conducted on a 1.5-Tesla
scanner (Sonata, Siemens, Erlangen, Germany) and
typically included T1-weighted (repetition time (TR)=
1,860 ms, echo time (TE)=4.38 ms with 1.2 mm slice
thickness, 256×192 matrix), T2-weighted, fast spin
echo (6,600 ms/100–110 ms, 2 mm slice thickness,
320×240 matrix) sequences, diffusion-weighted and
contrast-enhanced images. Post-contrast images were
acquired immediately after contrast agent injection
(Omniscan, Dotarem, 0.1 mmol/kg) with comparable
intervals between injection of contrast media and data
acquisition.
Diffusion-weighted images (DWI) were obtained with
diffusion-sensitizing gradients in three orthogonal direc-
tions, using a TR of 2,600 ms, a TE of 78 ms, FOVof 230×
230 mm, slice thickness of 5 mm, a gap of 1.5 mm, matrix
of 128×128, and three different b values (0, 500, and
1,000 mm2/s). Maps of apparent diffusion coefficient were
automatically calculated by the MR scanner.
MRI post-processing procedures Contrast-enhanced lesions
in T1-weighted images and hyperintense T2 (hT2) lesions
were segmented and the volumes were calculated using a
semi-automated active contour method (ITK-SNAP 2.0)
called snake evolution. “Snake” is a 3-D description of a
closed curve or surface that represents a segmentation. The
snake starts as a very rough estimate of the anatomical
structure of interest and continues to a close approximation
of the structure. Evolution of the snake is governed by a
mathematical equation describing the velocity of every
point on the snake at any particular time. The velocity of
each point depends on the shape of the snake and the
intensities of the image in the neighborhood of the point.
This segmentation tool demonstrated excellent reliability
and high efficiency of 3D segmentation [17]. Our response
evaluation aimed to calculate the absolute tumor volumes
because tumor volume calculations, but not linear or two-
dimensional measurements, proved to be an accurate
predictor of survival in patients with recurrent malignant
glioma [18]. For exact MRI response assessment during B/I
therapy, the calculated T1 and hT2 volumes were analyzed
according to Macdonald [4] and RANO criteria [5].
Because bevacizumab treatment has been reported to
induce diffuse gliomatotic tumor progression [19], the
hyperintense T2 volumes served as a basis for further
ADC analysis. The segmented T2 hyperintense (hT2)
volumes served as regions of interest (ROI) and were
registered to the corresponding ADC maps (hT2-ADC) by
applying an affine transformation using a mutual informa-
tion approach with 3D Slicer Software [20, 21]. This
provided information about the ADC gray value distribu-
tion within an hT2 volume, and the mean ADC was
calculated. To quantify and analyze the heterogeneous ADC
distribution within certain tumor regions, we calculated
histograms of the hT2-ADC ROIs.
Statistics For comparison of the histogram shapes, a
statistical parameter called skewness was used. The
skewness γ is a measure of the graph asymmetry of
discrete functions and can be calculated as
g ¼
1
n
Pn
i¼1
ximð Þ3
1
n
Pn
i¼1
ximð Þ2
 3
2
;
where n represents the number of values, xi the i-th value,
and μ the sample mean. Qualitatively, positive skewness
indicates that the majority of the values lie to the left of the
mean, while negative skewness indicates that the majority
of the values lie to the right side of the mean (Fig. 1).
The skewness of the hT2-ADC histograms was calcu-
lated for each baseline and follow-up MRI scan. Subse-
quently, the change in skewness in percentage was
analyzed. An increase in skewness indicated that the
skewness values became more positive at the follow-up
scan as compared with the baseline MRI. A decrease in
skewness means the values became more negative at
follow-up.
The statistical calculations were based on a median
survival of 6 months for rHGG and previous bevacizumab
response rates [3].
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The patient cohort was divided into two groups accord-
ing to PFS at 6 months (progressors, PFS <6 months;
responders, PFS≥6 months). The statistical significance of
value differences between the groups was obtained with the
Mann–Whitney U Test (MWU) at a 95% significance level.
A p value <0.05 was deemed to be statistically significant.
Skewness accuracy in predicting failure to therapy was
calculated by cross tabulation, and sensitivity and specific-
ity values were obtained.
For evaluation of the prognostic significance of varia-
bles, progression-free survival (PFS) and PFS6 (progres-
sion-free survival at 6 months) are more reliable study
endpoints than are overall survival (OS) and overall
survival at 12 months because after tumor progression
various salvage therapy approaches are used [22].
Analysis and statistical figures were calculated with
SPSS 16.0 for Windows (SPSS Inc., Chicago, IL).
Results
T1 post-contrast and T2 volumetry (Table 2) Median T1
contrast-enhanced tumor volume prior to B/I treatment was
16.5 cm3 (ranging from 0.6 to 105.6 cm3) as compared to
5.9 cm3 (range, 0.4 to 112.6 cm3) following 8–12 weeks of
B/I treatment. According to Macdonald criteria, nine
(64.3%) patients showed a partial response, four (28.6%)
patients had stable disease, and one (7.1%) patient showed
tumor progression. Median hT2 tumor volume prior to B/I
treatment was 130.6 cm3 (range, 43.3–218.2 cm3) and 8–
12 weeks after commencement of B/I treatment 122 cm3
(range, 29–258.7 cm3). According to RANO criteria, seven
(50%) patients showed partial response, three (21.4%)
patients, stable disease; and four (28.6%) patients, tumor
progression. The three patients (nos. 3, 5, and 15; Table 2),
who account for the disagreement between Macdonald and
RANO criteria, developed a solely T2 hyperintense tumor
progression, consistent with a gliomatotic tumor growth
pattern.
Overall tumor ADC (Table 3) According to PFS at
6 months (PFS 6), the patient population was divided into
two groups; 11 patients showed a progress at 6 months
(“progressors”), and three patients showed a response or a
stable disease at 6 months’ follow-up (“responders”).
Overall tumor ADC for baseline and follow-up MRI scans
are listed in Table 3. The median ADC value in 10−5×
mm2/s for progressors was 126.5 at baseline and 112 at
follow-up. By comparison, responders showed a median
ADC in 10−5×mm2/s of 113.3 at baseline and 136.4 at
follow-up. The median percentage change in ADC values
between baseline and follow-up was −6.8% as compared
with that in non-progressors with a median ADC increase
of +7.9% (p=0.04, MWU test; Fig. 2).
Skewness in ADC histograms Median skewness in pro-
gressors (PFS <6 months) prior to B/I treatment was 0.82
compared to 1.40 at follow-up, resulting in a median
increase in skewness of +54%. Median skewness in
responders (PFS≥6 months) prior to B/I treatment was 2.1
at baseline and 1.5 at follow-up, resulting in a decrease in
skewness of −3% (Table 3). The MWU test showed the
median percentage change in skewness in progressors to be
significantly greater (p=0.04) than in responders (Fig. 3). In
conclusion, an increase in skewness predicted early therapy
failure. Cross tabulation revealed a sensitivity of 72% and a
specificity of 67%.
Figure 4 describes a typical hT2-ADC histogram pattern
for early tumor progression. In this patient (no. 7, bifrontal
GBM, WHO IV), the T1 contrast-enhanced tumor volume
showed a 95% decrease 12 weeks after commencement of
B/I therapy (105.6 cm3 at baseline and 6.8 cm3 at follow-
up). In addition, hT2 volume showed a decrease from
150.7 cm3 to 85.1 cm3 12 weeks after starting B/I therapy
(volume reduction of 44%). Using RANO criteria, this
patient would be diagnosed as showing a partial response.
In the subsequent disease course, the patient’s neurological
condition worsened with progressive frontal lobe syndrome
and seizures. The MRI scan in week 16 detected almost no
contrast enhancement in T1, but hT2 volume had doubled
to 169.1 cm3. ADC map histogram analysis at baseline
revealed an even, uniform gray scale value distribution with
hardly any asymmetry and thus a low skewness of 0.32.
Twelve weeks after B/I treatment, a clear change in the
shape of the histogram could be detected. The histogram
Fig. 1 Skewness. Positive
skewness indicates that the ma-
jority of the values lie to the left
of the mean; negative skewness
indicates that the majority of the
values lie to the right of the
mean
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shape had become slim and peaked, had shifted to the left
side, and the skewness had become more positive with an
increase from 0.32 to 2.76 and 3.95 in weeks 0, 12, and 16,
respectively. This ADC histogram revealed the micro-
structural changes during anti-angiogenic treatment. At
baseline, prior to therapy, it shows the tumor volume
having a very heterogeneous gray scale distribution. By
contrast, 12 weeks after treatment, a homogeneous highly
cellular tumor mass can be detected.
Patients with stable disease or tumor response following
B/I treatment show no or hardly any change in skewness in
the ADC histograms. Figure 5 (patient no. 12) describes the
course of a patient with a steady decrease in the T1
contrast-enhanced volume as well as in hT2 volumes until
Table 2 Neuroimaging data and response assessment
Pat. Steroidsa MRI volumetry T1 post-contrast (cm3) b MRI volumetry T2 (cm3)b RANO criteriad
T B N MRI-pre MRI-2 Δ MRI-pre–MRI-2% Macdonald criteriac MRI-pre MRI-2 Δ MRI-pre–MRI-2%
1 + 7.3 1.8 −75.3 Partial response 151.1 168.2 11.3 Partial response
2 + 68.1 29.3 −57.0 Partial response 148.8 258.7 73.8 Progress
3 + 0.7 45.4 >1,000 Progress 97.5 110.1 13.0 Progress
4 + 17.8 6.6 −63.0 Partial response 105.5 147.0 39.3 Progress
5 + 12.6 3.5 −72.0 Partial response 143 82.9 −42.1 Partial response
6 + 54.1 5.3 −90.1 Partial response 180.5 154.3 −14.5 Partial response
7 + 105.6 6.8 −93.6 Partial response 150.7 85.1 −43.6 Partial response
8 + 4.4 2.9 −33.9 Stable 107.7 134.0 24.3 Stable
9 + 32.8 12.3 −62.4 Partial response 218.2 135.4 −37.9 Partial response
10 + 39.7 2.5 −93.8 Partial response 62.6 29.0 −53.7 Partial response
11 + 17.0 0.9 −94.9 Partial response 129.5 71.0 −45.2 Partial response
12 + 11.1 10.1 −9.1 Stable 67.6 53.5 −20.9 Stable
13 + 0.6 0.4 −43.0 Stable 131.7 135.8 3.1 Stable
14 + 16.0 11.5 −28.3 Stable 43.3 62.6 44.6 Progress
a Steroid treatment during neuroimaging: T throughout B/I treatment, B at commencement and discontinuation of B/I treatment, N never (dose range, 4–
16 mg dexamethasone); MRI magnetic resonance imaging
bMRI-pre MRI prior to B/I treatment, MRI 2 MRI after 8–12 weeks of B/I treatment
cMacdonald criteria [4]: complete response disappearance of all contrast-enhanced tumor lesions on consecutive MRI scans and the patient is off
corticosteroids and is neurologically stable or shows improvement, partial response ≥50% reduction in size of contrast-enhanced tumor lesions and the
patient is on a stable corticosteroid dose compared to the baseline scan and remains neurologically stable or shows improvement, progressive disease ≥25%
increase in size of contrast-enhanced tumor lesions or any new tumor on MRI scans or patient shows neurological deterioration with stable or increased
corticosteroid dose, stable disease includes all other conditions
d RANO criteria [5]: T2 or FLAIR sequences are included in MRI response assessment. Additionally to Macdonald criteria, complete or partial response
requires stable or improved non-enhanced (T2/FLAIR) lesions. Stable disease requires stable non-enhanced (T2/FLAIR) lesions. For progression, a
significant increase in non-enhanced (T2/FLAIR) lesions must be detectable
Pat. ADC histogram skewnessa ADC (10−5×mm2/s)a
MRI-pre MRI-2 Δ MRI-pre–MRI-2% MRI-pre MRI-2 Δ MRI-pre–MRI-2%
1 1.12 1.77 58 126.5 109.3 −14
2 2.37 1.87 −21 104.9 108.6 4
3 1.45 2.09 44 106.4 112.0 5
4 0.6 1.12 87 144.8 135.0 −7
5 1.38 1.38 0.0 118.7 131.0 10
6 0.82 1.05 28 132.5 127.8 −4
7 0.32 2.76 763 125.4 78.6 −37
8 2.10 2.03 −3 113.3 122.3 8
9 0.32 0.92 188 137.6 126.2 −8
10 2.67 1.50 −44 105.9 140.8 33
11 0.09 2.33 >1,000 145.2 103.4 −29
12 0.84 0.96 14 135.4 136.4 1
13 0.50 0.77 54 138.3 125.7 −9
14 1.99 1.40 −30 113.2 105.8 −7
Table 3 Apparent diffusion co-
efficient; absolute and histogram
skewness values
aMRI-pre prior to B/I treatment,
MRI-2 8–12 weeks after first B/I
treatment
Δ MRI-pre–MRI-2% difference
in % in ADC histogram skew-
ness
ADC apparent diffusion coeffi-
cient, MRI magnetic resonance
imaging
296 Neuroradiology (2011) 53:291–302
radiologic complete response after 14 cycles of B/I
treatment and 36 weeks treatment duration. At baseline,
the tumor is characterized by an even uniform hT2-ADC
histogram shape with a low skewness of 0.84. During the
course of treatment, the histogram shape and the skewness
do not change substantially. In week 36, the skewness
becomes even less positive and the shape shows a right-
hand shift. This reveals that the hT2 tumor volume has less
cellularity and the heterogeneous microstructural composi-
tion was maintained.
Discussion
This retrospective study shows that the change in ADC
histogram shape and asymmetry (skewness) derived from
T2 segmented MRI volumes reflects the heterogeneous
microstructural composition of a high-grade glioma and can
predict radiological response to anti-angiogenic treatment
early in the course of therapy.
MRI techniques are able to detect drug efficacy more
reliably and at an early time in the course of anti-angiogenic
treatment have great potential in clinical oncology practice
[23–26]. In recurrent high-grade glioma (rHGG), VEGF
pathway inhibition by means of bevacizumab not only
leads to an anti-tumor, but also to an anti-vascular effect
with the restoration of a highly permeable blood–brain
barrier. This results radiologically in contrast enhancement
withdrawal in T1 sequences and tumor edema reduction in
T2/FLAIR sequences. Therefore, the traditional morpho-
logic measurement of contrast-enhanced tumor volume
(Macdonald criteria) and even changes in T2/FLAIR
sequences (RANO criteria) may not assess true treatment
response [5, 27–29]. Despite intense investigations, no
reliable neuroimaging biomarkers predictive and/or prog-
nostic of anti-angiogenic treatment response have been
established so far [30, 31].
Imaging parameters derived from DW-MRI offer ap-
pealing imaging biomarkers [32] because the acquisition is
non-invasive, does not require any exogenous contrast
agents or ionizing radiation, is quantitative, and shows high
reproducibility [8, 12]. The apparent diffusion coefficient
(ADC), which quantifies overall diffusion (equal to water
mobility) occurring within each voxel, is able to detect
early microstructural tissue changes associated with cell
death [33, 34]. These changes contribute to altered cell
density, a histological feature having an inverse relationship
to ADC [35]. Increasing ADC values with successful
therapy have been reported at several anatomic sites,
including breast cancer [36, 37], renal cancer [38, 39],
primary sarcoma of bone [40], and in brain malignancies
[41–43]. Latest studies by Jain et al. demonstrated that
patients with rHGG, who were treated with anti-angiogenic
therapy and did not respond to therapy, showed a
significant decrease in mean ADC values [14].
This study compared Macdonald and RANO criteria to
reveal an anticipated discrepancy in response assessment.
When applying Macdonald criteria, nine (60%) patients
showed a partial response, four (28.6%) patients had stable
disease, and one (7.1%) patient showed disease progres-
sion. In contrast, when using RANO criteria, seven (50%)
patients showed a partial response, three (21.4%) patients,
Fig. 3 ADC histogram skewness. ADC histogram skewness in
progressors and non-progressors during a period of 6 months.
Median change in skewness for progressors (n=11) is 54%
(range, −30–2,548%). Median change in skewness for non-
progressors (n=3) is −3% (range, −44–14%). There is a statisti-
cally significant difference between the two groups (p=0.04)
Fig. 2 ADC change. ADC in progressors and non-progressors over
a period of 6 months. Median change in ADC in progressors (n=
11) is –6.8% (range –37.3–10.3%). Median change in ADC in non-
progressors (n=3) is 7.9% (range: 0.7–33%). There is a statistically
significant difference between the two groups (p=0.04)
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stable disease; and four (28.6%) patients, tumor progression.
The three patients (21.4%; nos. 3, 5, and 15; Table 2) who
accounted for this disagreement developed a solely T2
hyperintense tumor progression with suppression of contrast
enhancement in T1, consistent with a gliomatotic tumor
growth pattern. These findings are in line with literature
reports that describe an altered tumor recurrence pattern
during or after VEGF pathway-inhibiting treatment strategies
[44–47]. Such a gliomatotic growth pattern is characterized
by a decrease in the size of the contrast-enhanced, but an
increase in the size of the non-enhanced part of the tumor.
Recent radiologic–histopathologic correlation studies in T2
hyperintense regions showed a phenotypic shift in malignant
glioma growth to a predominantly infiltrative tumor type
independently of tumor angiogenesis [19]. These findings
suggest that T2 signal abnormality and increasing T2 volume
in the course of anti-angiogenic treatment are mainly due to
VEGF-independent glioma cell infiltration and not to
increasing tumor edema. T2 signal abnormalities, however,
in the context of heavily pre-treated HGG, are difficult to
interpret, which is why ADC histograms generated from
DWI-MRI and T2 hyperintense tumor volumes were used to
further characterize morphological microstructural changes
during anti-angiogenic treatment.
This study demonstrates that during the course of anti-
angiogenic treatment, the overall ADC values decrease
Fig. 4 Patient no. 7 from Table 2. a, e, i, l, p, t T1 post-contrast MRI
sequence, in blue: segmented T1 post-contrast volume at baseline, 12,
16, 28, 40, and 52 weeks after commencement of B/I therapy. b, f, j,
m, q, u T2 MRI sequence prior to B/I treatment, in magenta:
segmented T2 volume at baseline, 12, 16, 28, 40, and 52 weeks after
commencement of therapy. c, g, k, n, r, v ADC map, in small;
segmented T2 volume, registered to corresponding ADC maps at
baseline, 12, 16, 28, 40, and 52 weeks after commencement of B/I
therapy. d, h, l, o, s, w histogram of segmented T2 volume; gray scale
count gives the number of gray scales for the T2 volume
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(−6.8%) in progressors as compared to non-progressors
(+7.9%). Although the patient population is quite small,
with 11 progressors and three responding patients at
6 months, these results are in line with previous studies
[13, 14].
However, because of the very heterogeneous biological
nature of heavily pre-treated HGGs in different regions
within the same tumor, alterations in ADC values are not
only dependent on changing cellular density caused by cell
death [48]. Diffusivity is influenced by necrosis, microcyst
formation, edema, reactive gliosis, hemorrhage, and
treatment-related leukoencephalopathy [14]. This implies
that evaluation of mean ADC values of the entire tumor
mass is not as meaningful as it is in ADC gray scale
analysis of certain tumor areas. Therefore, this study went
one step further and analyzed the ADC gray scale
distribution and calculated and displayed it by means of
ADC histograms. ADC histogram analysis revealed
changes in histogram shape during the course of anti-
angiogenic treatment. In cases of tumor progression, the left
tail of the histogram developed more steeply than did the
right tail and the histograms became slim and peaked. A
former heterogeneous gray scale distribution became more
homogeneous with a peak at low ADC values. We
measured the degree of histogram asymmetry using the
statistical parameter skewness [49]. An increase in skew-
Fig. 5 Patient no. 12 from Table 2. a, e, i, l, p, t T1 post-contrast MRI
sequence, in blue: segmented T1 post-contrast volume at baseline, 12,
16, 28, 40, and 52 weeks after commencement of B/I therapy. b, f, j,
m, q, u T2 MRI sequence prior to B/I treatment, in magenta:
segmented T2 volume at baseline, 12, 16, 28, 40, and 52 weeks after
commencement of therapy. c, g, k, n, r, v ADC map, in small;
segmented T2 volume, registered to corresponding ADC maps at
baseline, 12, 16, 28, 40, and 52 weeks after commencement of B/I
therapy. d, h, l, o, s, w histogram of segmented T2 volume; gray scale
count gives the number of gray scales for the T2 volume
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ness (histogram shift to the left side) was significantly
associated with a PFS of less than 6 months (progressors).
Patients with a PFS of more than 6 months showed no
change or even a decrease in skewness during therapy
(responders). The sensitivity for an increasing skewness to
predict failure to therapy, hence, PFS <6 months was 72%
and specificity was 67%. Our results indicate that a patient
with an increase in skewness at 8 weeks’ therapy is more
likely to experience tumor progression than a patient with
negative or stable skewness.
A decrease in mean ADC values and an increase in
positive skewness can be due to two reasons: First, anti-
angiogenic therapies in brain tumors cause an initial
reduction in vasogenic edema [29], which decreases the
extracellular space and therefore reduces ADC values. This
is certainly one reason for mean ADC reduction. However,
the peaked and slim histogram change cannot be due to a
diminished edema alone. Therefore, secondly, the positive
skewness is probably due to increased cellularity of the
tumor in one region, hence, glioma growth. Neuropatho-
logic examinations of HGG tissue following anti-
angiogenic therapies showed a decrease in tumor vascular-
ity and a lack of glomeruloid endothelial proliferations [19].
This indicates that continuous inhibition of VEGF-induced
angiogenesis may promote tumor cell “escape”, which
produces a VEGF-independent phenotype with hypercellu-
larity [19]. These findings may support our hypothesis that
positive skewness in ADC histograms is evidence of a
compact hypercellular tumor tissue with restricted diffusiv-
ity, which results from VEGF-independent gliomatotic
tumor growth—and bevacizumab therapy failure. Such
invading VEGF-independent tumor cells will not be
Fig. 5 continued.
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affected by anti-VEGF therapy regimens alone and will
require combinations of agents specifically targeting the
invasiveness of glioma cells.
In conclusion, this study entails the inevitable limi-
tations of any retrospective study. The number of patients
is limited; furthermore, the small study population is
heterogeneous with a high variability of therapies before
B/I treatment. Although parts of the methodical approach
and its reliability have been tested in former trials [6, 13,
15], the reliability of our method has to be further
evaluated in high-grade gliomas during “conventional”
treatment. The results in this small patient cohort and the
reliability of the method clearly have to be further
evaluated in major prospective clinical trials. Neverthe-
less, the results of our study not only support recently
published literature regarding increased frequency of
gliomatotic tumor growth during anti-angiogenic therapy
but may point to a new neuroimaging tool for early
detection of therapy failure. ADC gray scale histograms as
a display of cellular density and tissue composition could
be a potentially predictive biomarker for the early
assessment of infiltrative tumor growth and for identifying
responders to VEGF pathway-inhibiting treatment regi-
mens. There is a clear need to better understand these
changes at the histological level, and corresponding
prospective histopathologic correlation studies would help
address this issue.
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